Nelson E A S, Bloom David E, Mahoney Richard T
Department of Paediatrics, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong SAR, People's Republic of China.
Department of Global Health and Population, Harvard School of Public Health, Boston, Massachusetts, United States of America.
PLoS One. 2014 Feb 20;9(2):e89593. doi: 10.1371/journal.pone.0089593. eCollection 2014.
The Global Vaccine Action Plan will require, inter alia, the mobilization of financial resources from donors and national governments - both rich and poor. Vaccine Procurement Assistance (VPA) and Vaccine Procurement Baseline (VPB) are two metrics that could measure government performance and track resources in this arena. VPA is proposed as a new subcategory of Official Development Assistance (ODA) given for the procurement of vaccines and VPB is a previously suggested measure of the share of Gross Domestic Product (GDP) that governments spend on their own vaccine procurement.
To determine realistic targets for VPA and VPB.
Organization for Economic Co-Operation and Development (OECD) and World Bank data for 2009 were analyzed to determine the proportions of bilateral ODA from the 23 Development Assistance Committee (DAC) countries disbursed (as % of GDP in current US$) for infectious disease control. DAC country contributions to the GAVI Alliance for 2009 were assessed as a measure of multilateral donor support for vaccines and immunization programs.
In 2009, total DAC bilateral ODA was 0.16% of global GDP and 0.25% of DAC GDP. As a percentage of GDP, Norway (0.013%) and United Kingdom (0.0085%) disbursed the greatest proportion of bilateral ODA for infectious disease control, and Norway (0.024%) and Canada (0.008%) made the greatest contributions to the GAVI Alliance. In 2009 0.02% of DAC GDP was US$7.61 billion and 0.02% of the GDP of the poorest 117 countries was US$2.88 billion.
Adopting 0.02% GDP as minimum targets for both VPA and VPB is based on realistic estimates of what both developed and developing countries should spend, and can afford to spend, to jointly ensure procurement of vaccines recommended by national and global bodies. New OECD purpose codes are needed to specifically track ODA disbursed for a) vaccine procurement; and b) immunization programs.
《全球疫苗行动计划》尤其需要从捐助方和各国政府(无论富国还是穷国)筹集财政资源。疫苗采购援助(VPA)和疫苗采购基线(VPB)是两项可衡量政府在这一领域的表现并追踪资源的指标。VPA被提议作为官方发展援助(ODA)的一个新子类别,用于疫苗采购,而VPB是此前提出的衡量政府在自身疫苗采购上所花费的国内生产总值(GDP)份额的指标。
确定VPA和VPB的现实目标。
分析经济合作与发展组织(OECD)和世界银行2009年的数据,以确定23个发展援助委员会(DAC)国家双边官方发展援助用于传染病控制的支出比例(以当前美元计算占GDP的百分比)。评估DAC国家2009年对全球疫苗免疫联盟(GAVI Alliance)的贡献,以此衡量多边捐助方对疫苗和免疫计划的支持。
2009年,DAC双边官方发展援助总额占全球GDP的0.16%,占DAC GDP的0.25%。按GDP百分比计算,挪威(0.013%)和英国(0.0085%)用于传染病控制的双边官方发展援助支出比例最高,挪威(0.024%)和加拿大(0.008%)对全球疫苗免疫联盟的贡献最大。2009年,DAC GDP的0.02%为76.1亿美元,最贫穷的117个国家GDP的0.02%为28.8亿美元。
将GDP的0.02%作为VPA和VPB的最低目标,是基于对发达国家和发展中国家为共同确保采购国家和全球机构推荐的疫苗应支出且能够负担的支出的现实估计。需要新的经合组织用途代码来专门追踪为以下方面支出的官方发展援助:a)疫苗采购;b)免疫计划。